Evidence map›Paper›PMID 38057353›Full record

ArticleScientific reports2023

Vesical imaging reporting and data system (VI-RADS) could predict the survival of bladder-cancer patients who received radical cystectomy.

Juntao Zhuang, Lingkai Cai, Huanyou Sun, Qikai Wu, Kai Li, Ruixi Yu, Qiang Cao, Pengchao Li, Xiao Yang, Qiang Lu

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juntao Zhuang *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lingkai Cai *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huanyou Sun *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qikai WuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kai LiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ruixi YuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qiang CaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pengchao LiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiao YangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. yangxiao2915@163.com.
Qiang LuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. doctorlvqiang@njmu.edu.cn.

Funding

Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project JSPH-MA-2022-5Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project JSPH-MC-2021-15the National Natural Science Foundation of China 82072832, 82273152
6 · The paper itself

Abstract

Vesical Imaging Reporting and Data System (VI-RADS) shows good potential in determining muscle-invasive bladder cancer (MIBC) patients. However, whether VI-RADS could predict the prognosis of radical cystectomy (RC) patients has not been reported. Our purpose is to determine whether VI-RADS contributed to predict oncologic outcomes. In this retrospective study, we analysed the information of bladder cancer patients who admitted to our centre from June 2012 to June 2022. All patients who underwent multiparametric magnetic resonance imaging (mpMRI) and underwent RC were included. VI-RADS scoring was performed by two radiologists blinded to the clinical data. Patients' clinical features, pathology data, and imaging information were recorded. Kaplan-Meier method was used to estimate patients' overall survival (OS) and progression-free survival (PFS). Log-rank test was used to assess statistical differences. COX regression analysis was used to estimate risk factors. Ultimately, we included 219 patients, with 188 males and 31 females. The median age was 66 (IQR = 61-74.5) years. The VI-RADS scores were as follows: VI-RADS 1, 4 (1.8%); VI-RADS 2, 68 (31.1%); VI-RADS 3, 40 (18.3%); VI-RADS 4, 69 (31.5%); and VI-RADS 5, 38 (17.4%). Patients with VI-RADS ≥ 3 had poorer OS and PFS than those with VI-RADS < 3. The AUC of VI-RADS predicting 3-year OS was 0.804, with sensitivity of 0.824 and negative predictive value of 0.942. Multivariate COX analysis showed that VI-RADS ≥ 3 was risk factors for OS (HR = 3.517, P = 0.003) and PFS (HR = 4.175, P < 0.001). In the MIBC subgroup, patients with VI-RADS ≥ 4 had poorer OS and PFS. In the non-muscle invasive bladder cancer (NMIBC) subgroup, the prognosis of patients with VI-RADS ≥ 3 remained poorer. VI-RADS scores could effectively predict the survival of patients after RC.

Indexed as

Urinary BladderUrinary Bladder NeoplasmsAgedCystectomyFemaleHumansMagnetic Resonance ImagingMalePrognosisRetrospective Studies

Identifiers

PMID38057353
PMCPMC10700510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.